CDSCO issues alert against 62 substandard drugs; Samples from Lupin, Jackson Laboratories flagged
时间:2024-06-26 20:10:52 阅读(143)
The Central Drugs Standard Control Organisation (CDSCO) has flagged 62 drug samples as they failed the quality test. The alert was issued by the drug regulator for November 2023.
The drug regulator’s list, as seen by Financial Express.com, reveals that 1197 drug samples were tested, out of which 1133 samples were of standard quality. 62 samples were not of standard quality, one sample was spurious and one sample was misbranded.
According to the drug regulator, dissolution, disintegration and assay are some of the reason of drug test failure. Lupin, Jackson Laboratories, E.G. Pharmaceuticals, Konis Pharmaceuticals, Biozenta Lifesciences Pvt., Aristo Pharmaceuticals, and Cotec Healthcare are some of the companies whose drug failed the quality test.
The regulator also issued a revised drug Alert for May 2022 which Omeprazole (Delayed-Release) and Domperidone (Sustained Release) Capsules, manufactured by Dr. Reddy’s Laboratories. CDSCO maintains that the assay of Omeprazole and Domperidone is the reason of failure.
“The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. Thus, the product is purported to be spurious, however, the same is subject to outcome of investigation,” it stated.
The drug combination belongs to a group of medicines called gastrointestinal agents used to treat heartburn, indigestion, epigastric pain, gastro-oesophageal reflux disease (GERD), peptic ulcers and Zollinger-Ellison syndrome.
上一篇:Nifty could take a breather but may resume uptrend towards 18100; Bank Nifty support seen at 41200
下一篇:YearEnder2023- From Barbie to Koffee with Karan, a sneak peek into CGI ads rolled out this year
猜你喜欢
- Nifty hits 21k high, faces bearish pressure; Bank Nifty surges to 48,200, overbought signals emerge
- Rupee opens higher, may appreciate on weak dollar, declining crude oil prices; USDINR to trade in this range
- Rupee trades in narrow range against US dollar in early trade
- Rupee likely to appreciate against dollar amid strong cues; USDINR may trade sideways in this range
- Rupee rises 4 paise against US dollar in early trade
- Rupee opens 6 paise higher against US dollar, may trade range-bound amid mixed cues
- Rupee likely to remain rangebound on strong dollar, FII outflows; USDINR pair to trade sideways in this range
- Rupee rises 33 paise to close at 82
- Rupee rises 43 paise to 81